Pertussis Market Poised for Expansion Through 2034 - Market Insight, Epidemiology, and Forecast | DelveInsight

Pertussis, commonly known as whooping cough, remains a significant public health concern globally despite widespread vaccination efforts. Caused by Bordetella pertussis, the disease is highly contagious and poses serious risks, especially to infants, young children, and immunocompromised individuals. The resurgence of pertussis in several high-income countries over the past decade underscores ongoing challenges in long-term immunity and disease control.
DelveInsight's latest report, "Pertussis - Market Insight, Epidemiology, and Market Forecast - 2034," offers an in-depth analysis of the disease's burden and evolving therapeutic landscape across major markets, including the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. The report presents detailed segmentation by age groups, vaccination status, and risk categories, alongside historical and projected epidemiological trends.

Vaccination remains the cornerstone of pertussis prevention. However, waning immunity from acellular vaccines and under-vaccination in certain populations have led to periodic outbreaks. Booster immunization strategies, maternal vaccination during pregnancy, and targeted interventions for adolescents and adults are increasingly being implemented to reduce disease incidence.

The pertussis market is expected to experience steady growth through 2034, driven by rising disease awareness, improved surveillance systems, advancements in vaccine technology, and increasing healthcare initiatives targeting adult immunization. Pipeline innovations include next-generation vaccines aimed at inducing longer-lasting immunity, as well as potential therapeutic agents to mitigate disease severity in high-risk patients.

DelveInsight foresees a dynamic market landscape with emerging opportunities for both vaccine developers and public health stakeholders. As global efforts intensify to curb resurgence and protect vulnerable populations, the pertussis market is likely to evolve significantly over the coming decade.

Request a sample and uncover the latest breakthroughs shaping the Pertussis market landscape and future outlook @ https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Pertussis Market Report:
• In 2023, the pertussis market size across the 7MM was approximately USD 259 million, expected to grow significantly by 2034.
• Between 2010 and 2019, an average of 170,000 pertussis (whooping cough) cases were reported annually.
• During the COVID-19 pandemic (2020-2023), pertussis cases dropped to an average of 80,227, a decrease of about 50%.
• After the pandemic, pertussis cases began to rise again, with 63,024 cases in 2022 and 158,910 cases in 2023.
• In January 2025, ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most advanced next-generation intranasal pertussis vaccine for whooping cough, announced that following a Type C meeting with the U.S. FDA in December 2024, ILiAD and hVIVO plc have signed a Letter of Intent (LOI) to conduct a pivotal Phase 3 human challenge trial for BPZE1.
• Emerging therapies for Pertussis include BPZE1, BK1310/MT-2355, SIIPL Tdap, and others.
• Key companies involved in the treatment of Pertussis include Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet, and others.

To know in detail about the Pertussis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pertussis Overview
Pertussis, also known as whooping cough, is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It is characterized by severe, prolonged coughing fits often followed by a "whoop" sound during inhalation, particularly in children. Pertussis can affect individuals of all ages but is most severe in infants, young children, and those with compromised immune systems, sometimes leading to serious complications or death.

Pertussis spreads through respiratory droplets from coughing or sneezing. It is highly contagious, with an infected person capable of spreading the disease to 80-90% of unvaccinated close contacts. The incubation period typically ranges from 7 to 10 days (up to 21 days).

Get a free sample for the Pertussis market forecast, size & share analysis report: https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pertussis Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Pertussis Epidemiology Segmentation:
The Pertussis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Pertussis Vaccination coverage

Pertussis Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Pertussis throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Pertussis drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Pertussis, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Pertussis therapeutics.

Explore how emerging Pertussis therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pertussis Market Outlook
The Pertussis market continues to evolve as vaccination remains the cornerstone of prevention, yet challenges persist in achieving complete and long-lasting immunity. The current immunization landscape features a combination of diphtheria, tetanus, and pertussis vaccines (DTaP, Tdap, and Td), replacing the earlier whole-cell pertussis (wPV) vaccines, which, despite their superior efficacy, were associated with significant adverse effects. Although safer acellular pertussis vaccines (aPV) have largely replaced wPV in high-income regions, cost barriers still lead many lower-income countries to rely on wPV formulations.

Treatment of pertussis remains primarily supportive, with antibiotics such as erythromycin, azithromycin, and clarithromycin used to reduce transmission, though they have limited impact on established symptoms. The prolonged disease course in severe cases continues to drive the need for better therapeutic interventions.

In the US, the FDA has approved a range of combination vaccines-including Pentaxim, Infanrix, Pentacel, and Vaxelis-providing protection against multiple diseases alongside pertussis. However, despite strong vaccination programs, studies indicate that pertussis remains prevalent among certain adult populations, particularly in Europe, highlighting the need for improved booster strategies and next-generation vaccines.

Looking ahead, the global pertussis market is expected to witness steady growth through 2034, driven by ongoing vaccine innovation, rising awareness of adult and maternal immunization, and the increasing demand for more effective and longer-lasting pertussis prevention. Pharmaceutical companies and public health agencies continue to prioritize closing immunity gaps across all age groups, offering significant opportunities for advancements in this market.

Pertussis Market Drivers
• Widespread adoption of routine immunization programs for infants and adolescents, including combination vaccines (DTaP, Tdap), is driving steady market demand. Efforts to expand vaccination coverage to pregnant women and adults further fuel the market's growth, as public health campaigns aim to close immunity gaps and reduce transmission across all age groups.
• Growing awareness of pertussis resurgence among adolescents and adults is prompting greater emphasis on booster vaccinations. Public health authorities in the US and Europe are recommending adult Tdap boosters and maternal vaccination, stimulating demand for both pediatric and adult vaccines and creating new market opportunities.

Pertussis Market Barriers
• Despite high initial efficacy, current acellular pertussis vaccines (aPV) demonstrate waning immunity over time, particularly in adolescents and adults. This limitation leads to increased breakthrough infections and underscores the need for next-generation vaccines, but also dampens long-term confidence in existing products.
• In many low- and middle-income countries, the high cost of acellular vaccines limits access, leading to continued reliance on whole-cell pertussis vaccines (wPV), which have higher side effect profiles. Economic barriers to adopting newer, safer vaccines impede global market expansion and highlight inequities in pertussis prevention efforts.

Scope of the Pertussis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Pertussis Companies: Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet, and others.
• Key Pertussis Therapies: BPZE1, BK1310/MT-2355, SIIPL Tdap, and others.
• Pertussis Therapeutic Assessment: Pertussis currently marketed, and Pertussis emerging therapies.
• Pertussis Market Dynamics: Pertussis market drivers and Pertussis market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Pertussis Unmet Needs, KOL's views, Analyst's views, Pertussis Market Access and Reimbursement.

To learn more about Pertussis companies working in the treatment market, visit @ https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Pertussis Market Report Introduction
2. Executive Summary for Pertussis
3. SWOT analysis of Pertussis
4. Pertussis Patient Share (%) Overview at a Glance
5. Pertussis Market Overview at a Glance
6. Pertussis Disease Background and Overview
7. Pertussis Epidemiology and Patient Population
8. Country-Specific Patient Population of Pertussis
9. Pertussis Current Treatment and Medical Practices
10. Pertussis Unmet Needs
11. Pertussis Emerging Therapies
12. Pertussis Market Outlook
13. Country-Wise Pertussis Market Analysis (2020-2034)
14. Pertussis Market Access and Reimbursement of Therapies
15. Pertussis Market Drivers
16. Pertussis Market Barriers
17. Pertussis Appendix
18. Pertussis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.